Absolute Risk of Atypical Fractures is Low in Bisphosphonate Users
Publish date: March 8, 2011
FROM JAMA
One of the coauthors – Muhammad M. Mamdani, Pharm.D., – reported financial relationships with Boehringer Ingelheim, Janssen-Ortho, Novartis, and Pfizer. The study was funded by the Ontario Ministry of Health and Long-Term Care.
